The Chicago Board Options Exchange (Cboe) filed to list shares of Canary Capital’s proposed staked Injective exchange-traded fund (ETF), expanding regulated crypto investment products in the US. The fund aims to accrue staking rewards by offering validation services using an approved platform. If approved, it would be the third staked altcoin ETF.

The SEC has yet to formally acknowledge the ETF filings from Canary Capital and Cboe, with potential key deadlines for a response in early September. The SEC’s review period can extend up to 240 days, delaying the final decision on the staked INJ ETF possibly until March 2026. The SEC ruled in May that staking does not violate securities laws.

If approved, Canary Capital’s ETF could give traditional investors exposure to the Injective protocol’s governance token, potentially boosting liquidity and visibility. INJ is currently trading at $15.10, down over 71% from its all-time high of $52. For Bitcoin, ETF inflows accounted for about 75% of new investment when its price rose above $50,000 in February 2024.

Ether’s price fell over 38% in the two weeks after the spot ETFs debuted for US trading in 2024, before starting to recover. Grayscale’s Ether ETF has seen significant selling pressure, with over $4.3 billion in net negative outflows. The market response to Ethereum’s spot ETF has been more muted compared to Bitcoin.

Read more at Cointelegraph: CBOE files for Staked INJ ETF on behalf of Canary Capital